Monopar Therapeutics Inc. (MNPR) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on two primary areas: ALXN1840, a late-stage oral treatment for Wilson disease, and a pipeline of radiopharmaceuticals targeting uPAR-expressing cancers (MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac). The company has no approved products and has not generated any revenue to date.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(2.45) million | $(5.08) million | $(3.36) million |
| Operating Expenses | $(3.23) million | $(6.46) million | $(3.51) million |
| Interest Income | $0.78 million | $1.38 million | $0.16 million |
| Cash & Equivalents (End of Period) | $39.5 million (as of June 30, 2025) | ||
| Total Investments | |||
| Total Liquidity (Cash + Investments) | $53.3 million | ||
| Accumulated Deficit | $(80.9) million | ||
| Debt | None (Operating lease liabilities only) |
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses for the six months ended June 30, 2025, rose to $6.46 million from $3.51 million in the prior year period. This increase was driven by higher R&D personnel costs (including stock-based compensation) and a significant increase in G&A expenses due to Board compensation grants and legal fees.
- Higher Interest Income: Interest income surged to $1.38 million YTD 2025 from $0.16 million YTD 2024, attributed to higher bank balances and interest earned on U.S. Treasury securities following capital raises in late 2024.
- License Payment: The company paid the remaining $3.0 million of the upfront cash consideration for the ALXN1840 license in January 2025, impacting cash flow from operations.
- Financing Activity: Unlike the prior year period, there were no sales of common stock under at-the-market sales agreements in the first half of 2025.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management estimates current cash and investments ($53.3 million) are sufficient to fund operations through December 31, 2026. No substantial doubt regarding going concern status exists as of the filing date.
- ALXN1840 Strategy: Following Alexion's termination of the program, Monopar has assumed full responsibility. The company is assembling a regulatory package to submit a New Drug Application (NDA) to the FDA in early 2026. Recent data presented at EASL 2025 supports sustained copper mobilization and safety.
- Radiopharmaceutical Progress:
- MNPR-101-Zr: Phase 1 imaging trial active; FDA authorized an Expanded Access Program (EAP) in June 2025.
- MNPR-101-Lu: Phase 1a therapeutic trial active and enrolling patients.
- MNPR-101-Ac: Late preclinical stage.
- Key Risks:
- Uncertainty of regulatory approval for ALXN1840 despite positive Phase 3 data, given Alexion's prior termination based on mechanistic trial reviews.
- Need for additional capital to fund development and commercialization beyond late 2026.
- Supply chain risks for radioisotopes (e.g., Actinium-225) and geopolitical impacts on manufacturing.
Investor Verification Checklist
- Verify the timeline and specific data requirements for the planned ALXN1840 NDA submission in early 2026 and the FDA's response to the transfer of IND sponsorship.
- Confirm the burn rate and cash runway assumptions, specifically whether the $53.3 million liquidity is sufficient to cover the NDA filing costs and continued clinical trials through end of 2026 without dilution.
- Review the terms of the ALXN1840 license agreement regarding the $94 million in potential milestone payments and 10-20% royalty obligations.
- Monitor enrollment rates and safety data for the MNPR-101-Zr Expanded Access Program and the Phase 1a MNPR-101-Lu trial.
- Assess the impact of the 1-for-5 reverse stock split (effective August 2024) on share count and liquidity for future financing.